Skip to content

Hepatectomy combined with hepatic vein resection and hepatic vein preservation for hepatocellular carcinoma (HCC): a randomized control trial

Hepatectomy combined with hepatic vein resection and hepatic vein preservation for hepatocellular carcinoma (HCC): a randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065957
Enrollment
Unknown
Registered
2022-11-19
Start date
2022-11-20
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Hepatic vein resection group:Combined hepatic vein resection
Hepatic vein preservation group:Hepatic vein preservation

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, hepatitis B virus infection; 2. Patients with hepatectomy combined with hepatic vein resection and patients with hepatectomy combined with hepatic vein preservation; 3. Child Pugh class A liver function, ICG15R <= 10%, Fibro scan liver hardness score <= F3; 4. The preoperative imaging (CT or MRI) examination showed that the distance from the edge of the liver tumor to the hepatic vein <= 1 cm or the hepatic vein was invaded; 5. Postoperative pathological type was hepatocellular carcinoma (HCC).

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. History of major abdominal surgery; 3. Multi-organ resection requirements (additional surgery to remove surrounding solid organs); 4. Other hepatitis viruses except hepatitis B or other hepatitis besides hepatitis B at the same time; 5. HCC patients have received interventional and/or chemotherapy and/or radiotherapy and/or targeted immunotherapy and/or microwave ablation and other non surgical resection treatments before surgery; 6. Patients with severe heart, lung, brain dysfunction and/or intolerable surgery; 7. Patients with recurrent and/or metastatic cancer after treatment of hepatocellular carcinoma; 8. Patients with liver tumor invading portal vein at the same time.

Design outcomes

Primary

MeasureTime frame
Postoperative functional recovery time;2 year Overall Survival (OS);

Secondary

MeasureTime frame
RFS, recurrence-free survival;the incidence of complications within 30 days after operation;mortality within 90 days after operation;

Countries

China

Contacts

Public ContactZhang Wen

The First Affiliated Hospital of Guangxi Medical University

wenzgxmu@163.com+86 13878108107

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026